These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30831135)

  • 1. Theranostic iRGD peptide containing cisplatin prodrug: Dual-cargo tumor penetration for improved imaging and therapy.
    Cho HJ; Park SJ; Lee YS; Kim S
    J Control Release; 2019 Apr; 300():73-80. PubMed ID: 30831135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging.
    Cho HJ; Lee SJ; Park SJ; Paik CH; Lee SM; Kim S; Lee YS
    J Control Release; 2016 Sep; 237():177-184. PubMed ID: 27349354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
    Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
    Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.
    Simón-Gracia L; Hunt H; Scodeller P; Gaitzsch J; Kotamraju VR; Sugahara KN; Tammik O; Ruoslahti E; Battaglia G; Teesalu T
    Biomaterials; 2016 Oct; 104():247-57. PubMed ID: 27472162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis.
    Qian J; Zhou S; Lin P; Lei J; Zheng S; Xu W; Wang Y; Gao Z; Yang J
    Drug Dev Res; 2023 Jun; 84(4):654-670. PubMed ID: 36959702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo design of a tumor-penetrating peptide.
    Alberici L; Roth L; Sugahara KN; Agemy L; Kotamraju VR; Teesalu T; Bordignon C; Traversari C; Rizzardi GP; Ruoslahti E
    Cancer Res; 2013 Jan; 73(2):804-12. PubMed ID: 23151901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligonucleotides--assembled Au nanorod-assisted cancer photothermal ablation and combination chemotherapy with targeted dual-drug delivery of Doxorubicin and Cisplatin prodrug.
    Shanmugam V; Chien YH; Cheng YS; Liu TY; Huang CC; Su CH; Chen YS; Kumar U; Hsu HF; Yeh CS
    ACS Appl Mater Interfaces; 2014 Mar; 6(6):4382-93. PubMed ID: 24559392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
    Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
    Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
    Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
    Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-penetrating iRGD facilitates penetration of poly(floxuridine-ketal)-based nanomedicine for enhanced pancreatic cancer therapy.
    Li X; Zhong H; Zheng S; Mu J; Yu N; Guo S
    J Control Release; 2024 May; 369():444-457. PubMed ID: 38575076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
    Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
    Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?
    Zhang WQ; Yu KF; Zhong T; Luo LM; Du R; Ren W; Huang D; Song P; Li D; Zhao Y; Wang C; Zhang X
    J Drug Target; 2015 Dec; 23(10):897-909. PubMed ID: 26087869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin Prodrug-Conjugated Gold Nanocluster for Fluorescence Imaging and Targeted Therapy of the Breast Cancer.
    Zhou F; Feng B; Yu H; Wang D; Wang T; Liu J; Meng Q; Wang S; Zhang P; Zhang Z; Li Y
    Theranostics; 2016; 6(5):679-87. PubMed ID: 27022415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
    Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
    Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
    Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
    J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-homing peptide iRGD-conjugate enhances tumor accumulation of camptothecin for colon cancer therapy.
    Singh T; Kim TW; Murthy ASN; Paul M; Sepay N; Jeong Kong H; Sung Ryu J; Rim Koo N; Yoon S; Song KH; Jun Baek M; Jeon S; Im J
    Eur J Med Chem; 2024 Feb; 265():116050. PubMed ID: 38128233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-penetrating iRGD peptide inhibits metastasis.
    Sugahara KN; Braun GB; de Mendoza TH; Kotamraju VR; French RP; Lowy AM; Teesalu T; Ruoslahti E
    Mol Cancer Ther; 2015 Jan; 14(1):120-8. PubMed ID: 25392370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer.
    Huang H; Dong Y; Zhang Y; Ru D; Wu Z; Zhang J; Shen M; Duan Y; Sun Y
    Theranostics; 2019; 9(4):1047-1065. PubMed ID: 30867815
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
    Hu C; Huang Y; Chen Y
    Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy.
    Puig-Saus C; Rojas LA; Laborda E; Figueras A; Alba R; Fillat C; Alemany R
    Gene Ther; 2014 Aug; 21(8):767-74. PubMed ID: 24942629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.